{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T12:36:53Z","timestamp":1648643813370},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T00:00:00Z","timestamp":1224115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chirurg"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00104-008-1556-0","type":"journal-article","created":{"date-parts":[[2008,10,14]],"date-time":"2008-10-14T23:37:11Z","timestamp":1224027431000},"page":"1047-1054","source":"Crossref","is-referenced-by-count":4,"title":["Heredit\u00e4res Mammakarzinom"],"prefix":"10.1007","volume":"79","author":[{"given":"B.","family":"Schlehe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schmutzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"1556_CR1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S et al. (2003) Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected f\u00fcr family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117\u20131130","journal-title":"Am J Hum Genet"},{"key":"1556_CR2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ygyno.2006.06.032","volume":"1033","author":"Bosse","year":"2006","unstructured":"Bosse K, Rhiem K, Wappenschmidt B et al. (2006) Screening for ovarian cancer by tranyvaginal ultrasound and serum CA125 measurement in woman with familial predisposition; a prospective cohort study. Gynecol Oncol 1033: 1077\u20131072","journal-title":"Gynecol Oncol"},{"key":"1556_CR3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 434(7035): 913\u2013917","journal-title":"Nature"},{"key":"1556_CR4","doi-asserted-by":"crossref","unstructured":"Carlson JW, Miron A, Jarboe EA et al. (2008) Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 26(25): 4160\u20134165","DOI":"10.1200\/JCO.2008.16.4814"},{"key":"1556_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","volume":"7","author":"Domchek","year":"2006","unstructured":"Domchek SM, Friebel TM, Neuhausen SL et al. (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet 7: 223\u2013229","journal-title":"Lancet"},{"key":"1556_CR6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nature05887","volume":"447","author":"Easton","year":"2007","unstructured":"Easton DF, Pooley KA, Dunning AM, Pharoah PD et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148): 1087\u20131093","journal-title":"Nature"},{"key":"1556_CR7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035): 917\u2013921","journal-title":"Nature"},{"key":"1556_CR8","doi-asserted-by":"crossref","unstructured":"Fong PC, Boss DS, Carden CP et al. (2008) AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. J Clin Oncol 26 [Suppl] Abstr 5510","DOI":"10.1200\/jco.2008.26.15_suppl.5510"},{"key":"1556_CR9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","volume":"340","author":"Hartmann","year":"1999","unstructured":"Hartmann LC, Schaid DJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77\u201384","journal-title":"N Engl J Med"},{"key":"1556_CR10","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"Hartmann","year":"2001","unstructured":"Hartmann LC, Sellers TA, Schadi DJ et al. (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93(21): 1633\u20131637","journal-title":"J Natl Cancer Inst"},{"key":"1556_CR11","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1038\/sj.onc.1208426","volume":"24","author":"Jones","year":"2005","unstructured":"Jones LP, Li M, Halama ED et al. (2005) Promotion of mammary cancer development by tamoxifen in a mouse model of BRCA1-mutation-related breast cancer. Oncogene 24: 3554\u20133562","journal-title":"Oncogene"},{"key":"1556_CR12","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME et al. (2002) Risk reducing salpingo-oophorectomy in women with a BRCA1 and BRCA2 mutation. N Engl J Med 346: 1609\u20131615","journal-title":"N Engl J Med"},{"key":"1556_CR13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","volume":"26","author":"Kauff","year":"2008","unstructured":"Kauff ND, Domchek SM, Friebel TM et al. (2008) Risk reducing Salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated Breast and Gynecologic Cancer: A multicenter, prospective Study. J Clin Oncol 26(8): 1331\u20131337","journal-title":"J Clin Oncol"},{"key":"1556_CR14","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"King","year":"2001","unstructured":"King MC, Wieand S, Hale K et al. (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251\u20132256","journal-title":"JAMA"},{"key":"1556_CR15","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1038\/sj.onc.1204812","volume":"20","author":"Lafarge","year":"2001","unstructured":"Lafarge S, Sylvain V, Ferrara M, Bignon YJ (2001) Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20(45): 6597\u2013606","journal-title":"Oncogene"},{"key":"1556_CR16","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","volume":"23","author":"Madalinska","year":"2005","unstructured":"Madalinska LB, Hollenstein J, Bleiker EM et al. (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23(28): 6890\u20136898","journal-title":"J Clin Oncol"},{"key":"1556_CR17","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.2001.19.19.3938","volume":"19","author":"McDonnell","year":"2001","unstructured":"McDonnell SK, Schaid DJ, Myers JL et al. (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19(19): 3938\u20133943","journal-title":"J Clin Oncol"},{"key":"1556_CR18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","volume":"345","author":"Meijers-Heijboer","year":"2001","unstructured":"Meijers-Heijboer H, van Geel B, van Putten WL et al. (2001) Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 and BRCA2 mutation. N Engl J Med 345: 159\u2013164","journal-title":"N Engl J Med"},{"key":"1556_CR19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","volume":"31","author":"Meijers-Hejboer","year":"2002","unstructured":"Meijers-Hejboer H, van den Ouweland A, Klijn J et al. (2002) Low penetrance susceptibility to breast cancer due to CHEK2 del1100delC in noncarriers of BRCA1 and BRCA2 mutations. Nat Genet 31: 55\u201359","journal-title":"Nat Genet"},{"key":"1556_CR20","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","volume":"22","author":"Metcalfe","year":"2004","unstructured":"Metcalfe K, Lynch HT, Ghadirian P et al. (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22: 2328\u20132335","journal-title":"J Clin Oncol"},{"key":"1556_CR21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","volume":"4","author":"Narod","year":"2004","unstructured":"Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4: 665\u2013676","journal-title":"Nat Rev Cancer"},{"key":"1556_CR22","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","volume":"24","author":"Pierce","year":"2006","unstructured":"Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA et al. (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated Stage I\/II Breast Cancer. J Clin Oncol 24(16): 2437\u20132443","journal-title":"J Clin Oncol"},{"key":"1556_CR23","first-page":"6221","volume":"63","author":"Quinn","year":"2003","unstructured":"Quinn JE, Kennedy RD, Mullan PB et al. (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63(19): 6221\u20136222","journal-title":"Cancer Res"},{"key":"1556_CR24","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 346: 1616\u20131622","journal-title":"N Engl J Med"},{"key":"1556_CR25","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","volume":"23","author":"Rebbeck","year":"2005","unstructured":"Rebbeck TR, Friebel T, Wagner T et al. (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23(31): 7804\u20137810","journal-title":"J Clin Oncol"},{"key":"1556_CR26","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"Risch","year":"2001","unstructured":"Risch HA, Mc Laughlin JR, Cole DE et al. (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68: 700\u2013710","journal-title":"Am J Hum Genet"},{"key":"1556_CR27","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr658","volume":"6","author":"Robson","year":"2003","unstructured":"Robson ME, Chappuis PO, Satagopan J et al. (2003) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1\/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6: R8\u2013R17","journal-title":"Breast Cancer Res"},{"key":"1556_CR28","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/ng1902","volume":"38","author":"Seal","year":"2006","unstructured":"Seal S, Thompson D, Renwick A et al. (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11): 1239\u20131241","journal-title":"Nat Genet"},{"key":"1556_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PRS.0b013e318177415e","volume":"122","author":"Spear","year":"2008","unstructured":"Spear SL, Schwarz KA, Venturi ML et al. (2008) Prophylactic mastectomy and reconstruction: clinical outcomes and patient satisfaction. Plast Reconstr Surg 122(1): 1\u20139","journal-title":"Plast Reconstr Surg"},{"key":"1556_CR30","unstructured":"Stufe-3-Leitlinien, Brustkrebsfr\u00fcherkennung in Deutschland (2008) In: Albert US (Hrsg) 1. Aktualisierung. W. Zuckschwerdt, M\u00fcnchen Wien New York"},{"key":"1556_CR31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","volume":"93","author":"van","year":"2005","unstructured":"van Sprundel TC, Schmidt MK, Rookus MA et al. (2005) Tollenaar RARisk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.Br J Cancer 93(3): 287\u2013292","journal-title":"Br J Cancer"},{"key":"1556_CR32","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","volume":"88","author":"Tassone","year":"2003","unstructured":"Tassone P, Tagliaferri P, Perricelli A et al. (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88(8): 1285\u20131291","journal-title":"Br J Cancer"},{"key":"1556_CR33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G","volume":"93","author":"Teraoka","year":"2001","unstructured":"Teraoka SN, Malone KE, Doody DR et al. (2001) Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and ovarian cancer. Cancer 93: 479\u2013487","journal-title":"Cancer"},{"key":"1556_CR34","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"Thompson","year":"2002","unstructured":"Thompson D, Easton DF (2002) Breast Cancer Linkage Consortium Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358\u20131365","journal-title":"J Natl Cancer Inst"},{"key":"1556_CR35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrc1321","volume":"4","author":"Ventikaraman","year":"2004","unstructured":"Ventikaraman AR (2004) Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer 4: 266\u2013267","journal-title":"Nat Rev Cancer"},{"key":"1556_CR36","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"The","year":"1999","unstructured":"The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91(15): 1310\u20131316","journal-title":"J Natl Cancer Inst"}],"container-title":["Der Chirurg"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-008-1556-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00104-008-1556-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-008-1556-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:23:19Z","timestamp":1558581799000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00104-008-1556-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,16]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1007\/s00104-008-1556-0","relation":{},"ISSN":["0009-4722","1433-0385"],"issn-type":[{"value":"0009-4722","type":"print"},{"value":"1433-0385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,16]]}}}